Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1525 to 1527 of 1527 entries
Sorted by: Best Match Show Resources per page
Childhood acute myeloid leukemia shows a high level of germline predisposition.

Blood

Samaraweera SE, Wang PPS, Li KL, Casolari DA, Feng J, Pinese M, Maung KZY, Leo P, Cowley M, Perkins K, Smith AM, Ellis J, Wee A, Hiwase DK, Scott HS, Schreiber AW, Brown AL, Deans AJ, Ross DM, Moore AS, Gonda TJ, Hahn CN, D'Andrea RJ.
PMID: 34521114
Blood. 2021 Dec 02;138(22):2293-2298. doi: 10.1182/blood.2021012666.

No abstract available.

Cite
Samaraweera SE, Wang PPS, Li KL, et al. Childhood acute myeloid leukemia shows a high level of germline predisposition. Blood. 2021;138(22):2293-2298doi: 10.1182/blood.2021012666.
Samaraweera, S. E., Wang, P. P. S., Li, K. L., Casolari, D. A., Feng, J., Pinese, M., Maung, K. Z. Y., Leo, P., Cowley, M., Perkins, K., Smith, A. M., Ellis, J., Wee, A., Hiwase, D. K., Scott, H. S., Schreiber, A. W., Brown, A. L., Deans, A. J., Ross, D. M., Moore, A. S., Gonda, T. J., Hahn, C. N., & D'Andrea, R. J. (2021). Childhood acute myeloid leukemia shows a high level of germline predisposition. Blood, 138(22), 2293-2298. https://doi.org/10.1182/blood.2021012666
Samaraweera, Saumya E, et al. "Childhood acute myeloid leukemia shows a high level of germline predisposition." Blood vol. 138,22 (2021): 2293-2298. doi: https://doi.org/10.1182/blood.2021012666
Samaraweera SE, Wang PPS, Li KL, Casolari DA, Feng J, Pinese M, Maung KZY, Leo P, Cowley M, Perkins K, Smith AM, Ellis J, Wee A, Hiwase DK, Scott HS, Schreiber AW, Brown AL, Deans AJ, Ross DM, Moore AS, Gonda TJ, Hahn CN, D'Andrea RJ. Childhood acute myeloid leukemia shows a high level of germline predisposition. Blood. 2021 Dec 02;138(22):2293-2298. doi: 10.1182/blood.2021012666. PMID: 34521114.
Copy Download .nbib Format: NLM
Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.

Annals of hematology

Moore DC, Nelson V, Muslimani A.
PMID: 33001279
Ann Hematol. 2021 Dec;100(12):3053-3055. doi: 10.1007/s00277-020-04285-y. Epub 2020 Oct 01.

No abstract available.

Cite
Moore DC, Nelson V, Muslimani A. Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma. Ann Hematol. 2020;100(12):3053-3055doi: 10.1007/s00277-020-04285-y.
Moore, D. C., Nelson, V., & Muslimani, A. (2021). Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma. Annals of hematology, 100(12), 3053-3055. https://doi.org/10.1007/s00277-020-04285-y
Moore, Donald C, et al. "Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma." Annals of hematology vol. 100,12 (2021): 3053-3055. doi: https://doi.org/10.1007/s00277-020-04285-y
Moore DC, Nelson V, Muslimani A. Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma. Ann Hematol. 2021 Dec;100(12):3053-3055. doi: 10.1007/s00277-020-04285-y. Epub 2020 Oct 01. PMID: 33001279.
Copy Download .nbib Format: NLM
High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial.

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

Papadopoulos E, Gillen J, Moore D, Au D, Kurgan N, Klentrou P, Finelli A, Alibhai SMH, Santa Mina D.
PMID: 34380000
Appl Physiol Nutr Metab. 2021 Dec;46(12):1535-1544. doi: 10.1139/apnm-2021-0365. Epub 2021 Aug 11.

This study assessed the feasibility of a phase II randomized controlled trial of high-intensity interval training (HIIT), resistance training (RT), and usual care (UC) in men with prostate cancer (PCa) on active surveillance and evaluated changes in clinically relevant...

Cite
Papadopoulos E, Gillen J, Moore D, et al. High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial. Appl Physiol Nutr Metab. 2021;46(12):1535-1544doi: 10.1139/apnm-2021-0365.
Papadopoulos, E., Gillen, J., Moore, D., Au, D., Kurgan, N., Klentrou, P., Finelli, A., Alibhai, S. M. H., & Santa Mina, D. (2021). High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 46(12), 1535-1544. https://doi.org/10.1139/apnm-2021-0365
Papadopoulos, Efthymios, et al. "High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial." Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme vol. 46,12 (2021): 1535-1544. doi: https://doi.org/10.1139/apnm-2021-0365
Papadopoulos E, Gillen J, Moore D, Au D, Kurgan N, Klentrou P, Finelli A, Alibhai SMH, Santa Mina D. High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial. Appl Physiol Nutr Metab. 2021 Dec;46(12):1535-1544. doi: 10.1139/apnm-2021-0365. Epub 2021 Aug 11. PMID: 34380000.
Copy Download .nbib Format: NLM
Showing 1525 to 1527 of 1527 entries